BELLUS Health Inc. (TSE:BLU)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$4.51 and traded as high as C$7.71. BELLUS Health shares last traded at C$7.63, with a volume of 133,292 shares changing hands.
BLU has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of BELLUS Health in a report on Monday, September 13th. They issued a “buy” rating and a C$13.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a C$14.00 price target on shares of BELLUS Health in a report on Tuesday, September 14th. Bloom Burton restated a “buy” rating on shares of BELLUS Health in a research report on Friday, August 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a C$8.00 target price on shares of BELLUS Health in a research report on Thursday, August 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of C$11.67.
The stock has a fifty day moving average of C$4.51 and a two-hundred day moving average of C$4.62. The company has a market capitalization of C$597.71 million and a PE ratio of -8.94. The company has a current ratio of 7.99, a quick ratio of 7.74 and a debt-to-equity ratio of 0.37.
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus.
Recommended Story: What are the disadvantages of after-hours trading?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.